Rossari Biotech Ltd

Rossari Biotech operates with a total equity of ₹13,333.49 million and total liabilities of ₹9,554.43 million, resulting in a debt-to-equity ratio of 0.33, which is relatively low compared to the industry median. The company holds ₹922.14 million in cash and equivalents, but its free cash flow is negative at ₹-391.03 million, indicating capital outflows. The operating cash flow of ₹650.68 million supports ongoing operations, but the negative free cash flow suggests reinvestment or expansion activities. The company's profitability is reflected in a return on equity (ROE) of 11.19% and a return on assets (ROA) of 6.52%. These figures are above the industry median for ROE and ROA, indicating strong returns relative to its peers. The gross profit of ₹7,276.38 million and operating income of ₹2,067.79 million support its profitability, with a net income of ₹1,492.13 million. The company's operating margin is 8.63%, and its net margin is 6.23%, both of which are in line with the industry average. Rossari Biotech operates through three segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). The HPPC segment produces acrylic polymers, while the TSC segment provides solutions for pre-treatment, dyeing, and printing in the textile industry. The AHN segment focuses on wellness solutions for pets and poultry. The company's revenue is primarily concentrated in India, with a significant portion derived from the FMCG sector. The company's flagship brand, Freshee, is a key product in the home and personal care segment. The company's revenue for the latest period is ₹23,963.65 million, with a growth trajectory that is expected to continue. The outlook for the current fiscal year (FY) is positive, with a projected revenue increase. The next FY is also expected to show growth, with a numeric delta of 10-15% in revenue. The company's capital expenditure of ₹-2,646.72 million indicates ongoing investment in infrastructure and expansion. The risk assessment for Rossari Biotech indicates a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt. The liquidity risk is primarily due to the negative free cash flow, which may impact the company's ability to meet short-term obligations. The dilution risk is low, as the company has not issued additional shares recently, and there is no indication of future dilution. Recent events and filings indicate that Rossari Biotech has maintained a stable financial position. The company's recent earnings call transcripts and investor relations communications highlight its focus on expanding its product portfolio and entering new markets. The company has also emphasized its commitment to sustainability and ESG practices, which align with its long-term growth strategy.